Pentixapharm Holding AG (XTER:PTP) ROCE %: -32.89% (As of Mar. 2026)


XTER:PTP Pentixapharm Holding AG XTER:PTP
12 GF Score
Price €2.10
! 2 Warning Signs
View Full Analysis

What is Pentixapharm Holding AG ROCE %?

Pentixapharm Holding AG XTER:PTP +4.48% 12 ROCE % is -32.89% as of Mar. 2026. GuruFocus rates XTER:PTP with a GF Score™ of 12/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pentixapharm Holding AG's annualized ROCE % for the quarter that ended in Mar. 2026 was -32.89%.

Pentixapharm Holding AG  (XTER:PTP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pentixapharm Holding AG ROCE % Related Terms

Pentixapharm Holding AG ROCE % Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG ROCE % Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-6.04 -1.93 -10.40 -27.90 -42.12

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -31.78 -38.61 -42.81 -63.85 -32.89
XTER:PTP
12GF Score
Pentixapharm Holding AG XTER:PTP
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG ROCE % Calculation

Pentixapharm Holding AG's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-19.513/( ( (68.304 - 14.041) + (41.859 - 3.459) )/ 2 )
=-19.513/( (54.263+38.4)/ 2 )
=-19.513/46.3315
=-42.12 %

Pentixapharm Holding AG's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-12.6/( ( (41.859 - 3.459) + (41.168 - 2.944) )/ 2 )
=-12.6/( ( 38.4 + 38.224 )/ 2 )
=-12.6/38.312
=-32.89 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -32.89% mean?
Pentixapharm Holding AG (XTER:PTP) has a ROCE % of -32.89% as of Mar. 2026.
Is Pentixapharm Holding AG's ROCE % too high?
Pentixapharm Holding AG's current ROCE % is -32.89%. Overall, Pentixapharm Holding AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's ROCE % compare to VRTX and REGN?
Pentixapharm Holding AG's ROCE % of -32.89% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Pentixapharm Holding AG's current ROCE % is -32.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current ROCE % of -32.89%. The current ROCE % is -32.89%. Pentixapharm Holding AG's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current ROCE % is -32.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
12GF Score

Get the complete analysis for XTER:PTP

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.10
Price